Effective and efficient nebulization of alpha1-proteinase inhibitor (alpha1-PI) for inhalation therapy using the AKITA2® APIXNEBÔ nebulizer system

N. Blazei, J. Gleske, B. Muellinger (Clayton, United States Of America; Gauting, Germany)

Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Session: Drug delivery and pharmacokinetics I
Session type: E-Communication Session
Number: 2025
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Blazei, J. Gleske, B. Muellinger (Clayton, United States Of America; Gauting, Germany). Effective and efficient nebulization of alpha1-proteinase inhibitor (alpha1-PI) for inhalation therapy using the AKITA2® APIXNEBÔ nebulizer system. Eur Respir J 2010; 36: Suppl. 54, 2025

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system]
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Optimization of inhalation treatment – Evaluation of influence of spacer integrated with the spirometer on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 2: Portable battery-compressor
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Characterization of the performance of a new portable jet nebulizer system for the delivery of budesonide suspension for nebulization
Source: Annual Congress 2008 - Wheezing in preschool children
Year: 2008

Peripheral deposition of α1-protease inhibitor using commercial inhalation devices
Source: Eur Respir J 2003; 22: 263-267
Year: 2003



Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012


Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 1: Table-top compressors
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012


Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM)
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006

Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011


Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation with oscillating positive expiratory pressure device (OPEP) offers potential for simultaneous therapy
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013


Fluticasone/salmeterol combined in the new Forspiro® inhaler is as effective and safe as Seretide® Accuhaler® in adult and pediatric asthmatics
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Chronic inhalation toxicity study of nebulized alpha1 proteinase inhibitor (alpha1-PI), TAL6005, in rodents
Source: Annual Congress 2010 - Models of airways disease
Year: 2010


Highly effective delivery of medication is possible in home use with improved breath-actuated nebulizer (BAN) driven by home compressor
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Successful conversion of patients using nebulised iloprost from multisonic nebuliser to adaptive aerosol delivery nebuliser
Source: Eur Respir J 2007; 30: Suppl. 51, 345s
Year: 2007

Efficiency of urgent nebulizer therapy of peakings bronchial allergy at children at a stage [dfoquote]an ambulance station - first aid[dfcquote]
Source: Eur Respir J 2001; 18: Suppl. 33, 456s
Year: 2001

Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013

Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013


In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011


Lung deposition of two bronchodilators in subjects with (COPD) when administered via standard jet nebulizer or Handihaler® using functional respiratory imaging (FRI).
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Reduction of nebulization time can be achieved with a new jet nebulizer design
Source: Eur Respir J 2006; 28: Suppl. 50, 211s
Year: 2006